Grail (NASDAQ:GRAL) vs. Sera Prognostics (NASDAQ:SERA) Head-To-Head Review

Sera Prognostics (NASDAQ:SERA) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Institutional and Insider Ownership

54.6% of Sera Prognostics shares are owned by institutional investors. 15.8% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Profitability

This table compares Sera Prognostics and Grail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	N/A	-51.73%	-36.94%
Grail	N/A	N/A	N/A

Valuation & Earnings

This table compares Sera Prognostics and Grail”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$94,000.00	1,523.33	-$36.24 million	($0.99)	-4.28
Grail	$125.60 million	10.32	N/A	N/A	N/A

Grail has higher revenue and earnings than Sera Prognostics.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Sera Prognostics and Grail, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	0	0	1	0	3.00
Grail	0	3	0	0	2.00

Grail has a consensus target price of $16.00, indicating a potential downside of 58.51%. Given Grail’s higher probable upside, analysts clearly believe Grail is more favorable than Sera Prognostics.

Summary

Sera Prognostics beats Grail on 5 of the 9 factors compared between the two stocks.

About Sera Prognostics

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

About Grail

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.